Clinical Pathways promote evidence based, safe, and high-value care for patients by providing clinical recommendations and standard processes. They are developed by multidisciplinary committees of subject matter experts, informed by methodical review of available evidence and consensus among committee members.
The Hyperglycemic Hyperosmolar Syndrome (HHS) synopsis provides a high-level overview of the care standards employed for this Clinical Pathway.
Algorithms associated with this Clinical Pathway:
- Severe hypoglycemia (glucose > 500)
- Effective serum osmolality > 350
- Serum bicarbonate > 16 mmol/L
Committee members involved in the development:
- M. Knoll, MD, MHPE | Endocrinology | Committee chair
- R. McDonough, DO | Endocrinology | Committee member
- A. Stoner, MS, DO | Critical Care Medicine | Committee member
- S. Fagan, RN, BSN, CCRN-K | Pediatric Intensive Care Unit | Committee member
MIT Committee Members:
- T. Frank, RPh, CPHIMS | Medical Informatics - Pharmacy | Committee member
EBP Committee Members:
- K. Berg, MD, FAAP | Hospitalist, Evidence Based Practice
- J. Bartlett, PhD, RN | Evidence Based Practice
- Megan Gripka, MT (ASCP) SM | Evidence Based Practice
- Kelli Reiling Ott, OTD, OTR/L | Evidence Based Practice
- Finalized date: 12/2022
- Next expected revision date: 12/2025
Concerns with content:
If you have any questions regarding this content or identify a broken link, please email firstname.lastname@example.org.